Identifying anti-growth factors for human cancer cell lines through genome-scale metabolic modeling

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Ghaffari, Pouyan ^a   Mardinoglu, Adil ^a   Asplund, Anna ^b   Shoaie, Saeed ^a   Kampf, Caroline ^b   Uhlen, Mathias ^c   Nielsen, Jens ^a,c  

^a CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE 1A, HUMAN; CPT1B PROTEIN, HUMAN; PERHEXILINE; RNA;

BIOLOGICAL MODEL; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; HUMAN GENOME; METABOLISM; TUMOR CELL LINE;

ANTIMETABOLITES; CARNITINE O-PALMITOYLTRANSFERASE; CELL LINE, TUMOR; CELL PROLIFERATION; GENOME, HUMAN; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; PERHEXILINE; RNA;

EID: 84936890106     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08183     Document Type: Article

References (56)

1. Jain, M. et al. Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation. Science 336, 1040-1044 (2012).
2. Moghaddas Gholami, A. et al. Global proteome analysis of the NCI-60 cell line panel. Cell Rep 4, 609-620 (2013).
3. Geiger, T., Wehner, A., Schaab, C., Cox, J. & Mann, M. Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins. Mol Cell Proteomics 11, M111 014050 (2012).
4. Hyduke, D. R., Lewis, N. E. & Palsson, B. O. Analysis of omics data with genomescale models of metabolism. Molecular bioSystems 9, 167-174 (2013).
5. Mardinoglu, A. & Nielsen, J. Systems medicine and metabolic modelling. Journal of internal medicine 271, 142-154 (2012).
6. Mardinoglu, A., Gatto, F. & Nielsen, J. Genome-scale modeling of human metabolism - a systems biology approach. Biotechnology journal 8, 985-996 (2013).
7. Shoaie, S. & Nielsen, J. Elucidating the interactions between the human gut microbiota and its host through metabolic modeling. Front Genetics 5, 86 (2014).
8. Duarte, N. C. et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci U S A 104, 1777-1782 (2007).
9. Thiele, I. et al. A community-driven global reconstruction of human metabolism. Nat Biotechnol 31, 419-425 (2013).
10. Mardinoglu, A. et al. Integration of clinical data with a genome-scale metabolic model of the human adipocyte. Mol Syst Biol 9, 649 (2013).
11. Mardinoglu, A. et al. Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nature communications 5, 3083 (2014).
12. Agren, R. et al. Reconstruction of Genome-Scale Active Metabolic Networks for 69 Human Cell Types and 16 Cancer Types Using INIT. Plos Comput Biol 8, e1002518 (2012).
13. Frezza, C. et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477, 225-228 (2011).
14. Gatto, F., Nookaew, I. & Nielsen, J. Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma. P Natl Acad Sci USA 111, E866-E875 (2014).
15. Agren, R. et al. Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol Syst Biol 10, 721 (2014).
16. Hanahan,D.&Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
17. Ward, P. S. & Thompson, C. B. Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate. Cancer Cell 21, 297-308 (2012).
18. Lazar, M. A. & Birnbaum, M. J. Physiology. De-meaning of metabolism. Science 336, 1651-1652 (2012).
19. Kaye, S. B. New antimetabolites in cancer chemotherapy and their clinical impact. British journal of cancer 78 Suppl 3, 1-7 (1998).
20. Hebar, A., Valent, P. & Selzer, E. The impact of molecular targets in cancer drug development: major hurdles and future strategies. Expert review of clinical pharmacology 6, 23-34 (2013).
21. Garg, D. et al. Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs. Journal of medicinal chemistry 53, 6539-6549 (2010).
22. Fagerberg, L. et al. Contribution of antibody-based protein profiling to the human Chromosome-centric Proteome Project (C-HPP). Journal of proteome research 12, 2439-2448 (2013).
23. Fagerberg, L. et al. Analysis of the Human Tissue-specific Expression by Genomewide Integration of Transcriptomics and Antibody-based Proteomics. Mol Cell Proteomics 13, 397-406 (2014).
24. Kampf, C. et al. Defining the human gallbladder proteome by transcriptomics and affinity proteomics. Proteomics 14, 2498-2507 (2014).
25. Mardinoglu, A. et al. Defining the human adipose tissue proteome to reveal metabolic alterations in obesity. J Proteome Res 13, 5106-5119 (2014).
26. Kampf, C. et al. The human liver-specific proteome defined by transcriptomics and antibody-based profiling. Faseb J 28, 2901-2914 (2014).
27. Lindskog, C. et al. The lung-specific proteome defined by integration of transcriptomics and antibody-based profiling. Faseb J 28, 5184-5196 (2014).
28. Folger, O. et al. Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol 7, 501 (2011).
29. Cantor, J. R. & Sabatini, D. M. Cancer cell metabolism: one hallmark, many faces. Cancer discovery 2, 881-898 (2012).
30. Hu, J. et al. Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nature biotechnology 31, 522-529 (2013).
31. Kruskal, W. H. &Wallis, W. A. Use of Ranks in One-Criterion Variance Analysis. J Am Stat Assoc 47, 583-621 (1952).
32. Hayter, A. J. The Maximum Familywise Error Rate of Fishers Least Significant Difference Test. J Am Stat Assoc 81, 1000-1004 (1986).
33. Feuerecker, B. et al. Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo. Cancer biology & therapy 13, 1425-1435 (2012).
34. Goraca, A. et al. Lipoic acid-biological activity and therapeutic potential. Pharmacological reports: PR 63, 849-858 (2011).
35. Mayr, J. A. et al. Lipoic acid synthetase deficiency causes neonatal-onset epilepsy, defective mitochondrial energy metabolism, and glycine elevation. American journal of human genetics 89, 792-797 (2011).
36. Schlossmacher, G., Stevens, A. & White, A. Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells. The Journal of endocrinology 211, 17-25 (2011).
37. Sionov, R. V., Spokoini, R., Kfir-Erenfeld, S., Cohen, O. & Yefenof, E.Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoidinduced apoptosis. Advances in cancer research 101, 127-248 (2008).
38. Spokoini, R., Kfir-Erenfeld, S., Yefenof, E. & Sionov, R. V. Glycogen synthase kinase-3 plays a central role in mediating glucocorticoid-induced apoptosis. Molecular endocrinology 24, 1136-1150 (2010).
39. Blomhoff, R. & Blomhoff, H. K. Overview of retinoid metabolism and function. Journal of neurobiology 66, 606-630 (2006).
40. Gudas, L. J. &Wagner, J. A. Retinoids regulate stem cell differentiation. Journal of cellular physiology 226, 322-330 (2011).
41. Tang, X. H. & Gudas, L. J. Retinoids, retinoic acid receptors, and cancer. Annual review of pathology 6, 345-364 (2011).
42. Goa, K. L., Brogden, R. N. l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Drugs 34, 1-24 (1987).
43. Pekala, J. et al. L-Carnitine-Metabolic Functions and Meaning in Humans Life. Curr Drug Metab 12, 667-678 (2011).
44. Vaz, F. M. &Wanders, R. J. Carnitine biosynthesis in mammals. The Biochemical journal 361, 417-429 (2002).
45. Bartlett, K.& Eaton, S.Mitochondrial beta-oxidation. Eur J Biochem 271, 462-469 (2004).
46. Jakobs, B. S., Wanders, R. J. A. Fatty-Acid Beta-Oxidation in Peroxisomes and Mitochondria - the First, Unequivocal Evidence for the Involvement of Carnitine in Shuttling Propionyl-Coa from Peroxisomes to Mitochondria. Biochem Bioph Res Co 213, 1035-1041 (1995).
47. Duran, M., Loof, N. E., Ketting, D. & Dorland, L. Secondary Carnitine Deficiency. J Clin Chem Clin Bio 28, 359-363 (1990).
48. McGarry, J. D. & Brown, N. F. The mitochondrial carnitine palmitoyltransferase system-From concept to molecular analysis. Eur J Biochem 244, 1-14 (1997).
49. Uhlen, M. et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 28, 1248-1250 (2010).
50. Kim, H. U. et al. Integrative genome-scale metabolic analysis of Vibrio vulnificus for drug targeting and discovery. Mol Syst Biol 7, 460 (2011).
51. Carracedo, A., Cantley, L. C. & Pandolfi, P. P. Cancer metabolism: fatty acid oxidation in the limelight. Nature reviews Cancer 13, 227-232 (2013).
52. Zaugg, K. et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes & development 25, 1041-1051 (2011).
53. Samudio, I. et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. The Journal of clinical investigation 120, 142-156 (2010).
54. Paumen, M. B. et al. Direct interaction of the mitochondrial membrane protein carnitine palmitoyltransferase I with Bcl-2. Biochem Biophys Res Commun 231, 523-525 (1997).
55. Santos, C. R. & Schulze, A. Lipid metabolism in cancer. The FEBS journal 279, 2610-2623 (2012).
56. Agren, R. et al. The RAVEN toolbox and its use for generating a genome-scale metabolic model for Penicillium chrysogenum. PLoS computational biology 9, e1002980 (2013).